2026-10-01 18:24:00 UTC#401055newconfirmedpress release
CVRX stock news
CVRX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire18 wire items
2026-09-21 20:23:04 UTC#345015duplicateconfirmednews
CVRx names John Landry as new CFO, succeeding Jared Oasheim
2026-09-21 20:19:31 UTC#344962duplicateconfirmednews
CVRx appoints John Landry as CFO, effective after Q3 2026 10-Q filing
2026-09-21 20:09:00 UTC#344910updateconfirmednews
CVRx confirms outgoing executive will remain through transition period
2026-09-21 20:09:00 UTC#344909newconfirmednews
CVRx appoints John Landry as CFO, effective following Q3 2026 10-Q filing
2026-09-21 20:08:00 UTC#344912duplicateconfirmednews
CVRx appoints John Landry as CFO to succeed Jared Oasheim
2026-08-25 00:06:03 UTC#214980duplicateconfirmednews
Duplicate: Jorey Chernett discloses 5.5% stake in CVRx, urges board to pursue sale
2026-08-24 12:30:00 UTC#212173newconfirmedpress release
CVRx 5.5% shareholder Jorey Chernett urges board to initiate formal sale process
pr_newswireimportance 0.60trust 0.90CVRx, Inc. +0.50Jorey Chernett +0.50Pointillist Family Office 0+1 entities
2026-08-14 19:42:00 UTC#179911newconfirmednews
Hagens Berman Investigating CVRx (CVRX) Following DOJ Inquiry, Revenue Guidance Cut, and 59% Stock Drop
pr_newswireimportance 0.60trust 0.70CVRx, Inc. -0.80Hagens Berman Sobol Shapiro LLP -0.10United States Department of Justice -0.50+2 entities
2026-08-11 18:53:38 UTC#160647updateconfirmedanalysis
CVRx addresses sales execution challenges and gains Humana payer coverage for heart failure device
2026-08-11 18:16:20 UTC#160521newconfirmedanalysis
CVRx heart failure device adoption supported by expanded Medicare coverage and ongoing clinical trials
2026-08-11 11:01:00 UTC#158136updateconfirmednews
CVRx Chief Revenue Officer Robert John to depart company
2026-08-11 11:01:00 UTC#158132newconfirmednews
CVRx, Inc. appoints Paul Verrastro as interim head of sales, effective immediately
2026-08-08 00:22:00 UTC#148086newconfirmednews
CVRx downgraded to Hold from Buy at Lake Street, price target slashed to $3.50 from $14.00
2026-08-07 13:05:19 UTC#145057newconfirmednews
CVRx issues 2026 revenue guidance of $58M-$60M, citing sales productivity and Medicare Advantage headwinds
2026-08-07 10:21:17 UTC#144082newconfirmednews
CVRx, Inc. average analyst price target cut to $9.60 from $11.17, 62% upside implied
2026-08-07 07:15:28 UTC#143124updateconfirmednews
CVRx Q2 revenue rises 16% to $15.7M; Humana adds Medicare Advantage coverage for Barostim device
2026-08-06 21:57:50 UTC#140847newconfirmeddata release